



# *Dag van de Tips*

*29 September 2018 - Gent*



Thomas Lienard  
CEO Bone Therapeutics



*New frontiers in orthopaedics  
and bone diseases*

# DISCLAIMER

This presentation has been prepared by Bone Therapeutics SA (the "Company") to provide an overview of the Company (and, together with its shareholders, subsidiaries and associated companies, the "Group"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting. This Presentation may not be copied, distributed, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's organisation or firm) or published in whole or in part, for any purpose or under any circumstances. This Presentation is an advertisement and not a prospectus. Save as set out below, the Presentation has been prepared on the basis of information held by the Group and also from publicly available information. This information, which does not purport to be comprehensive, has not been independently verified by or on behalf of the Group. The Presentation does not constitute an audit or due diligence review and should not be construed as such.

This Presentation contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates. Investors should not base their investment decision on this information. This Presentation also contains certain forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology or by their context. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analysis of estimates not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. The Company draws your attention to the fact that forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates may differ materially from those proposed or reflected in the forward-looking statements contained in this document and the accompanying oral presentation. Furthermore, even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document and the accompanying oral presentation, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. Certain figures and numbers appearing in this document and the accompanying oral presentation have been rounded. Consequently, the total amounts and percentages appearing in the tables are therefore not necessarily equal to the sum of the individually rounded figures, amounts or percentages.

Information relating to markets and other industry data pertaining to the Company's business included in this presentation has been obtained from internal surveys, scientific publications and publicly available information. The main sources for industry information were peer-reviewed publications, sector association studies and government statistics. Bone Therapeutics has not independently verified information obtained from industry and public sources. Certain other information in this presentation regarding the industry reflects the Company's best estimates based upon information obtained from industry and public sources. Information from the Company's internal estimates and surveys has not been verified by any independent sources."

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This document and its contents may not be viewed by persons within the United States (within the meaning of Regulation S under the Securities Act) other than (i) by QIBs (Qualified Institutional Buyers) or (ii) in "offshore transactions" within the meaning of Regulation S. This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. This document does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

By reviewing this document and attending the meeting where this Presentation is made, you warrant, represent, acknowledge and agree to and with the Company and the Banks that (i) you and any persons you represent are either (a) QIBs or (b) are located outside the United States, (ii) you have read, agree to and will comply with the contents of this disclaimer including, without limitation, the obligation to keep this Presentation and its contents confidential, and that you will abide by the terms of any additional agreement in respect of confidentiality and non-disclosure which you may be asked to sign and (iii) you will not at any time have any discussion, correspondence or contact concerning the information in this Presentation with any third party without the prior written consent of the Company.

# BONE THERAPEUTICS IN EEN NOTENDOP



Minimaal invasieve botcel-technologie



Gericht op **orthopedische** en **botaandoeningen** met **hoge medische noden**



Gevorderde klinische pijplijn in **Fase II** en **Fase III** voor **3 indicaties**



Sterk **IP Portofolio**, **Infrastructuur** en **know-how** in de **productie** van **celtherapeutische producten**



Jean Stéphenne



Ervaren **Management Team**,  
**Versterkte Raad van Bestuur**,  
~ 100 werknemers (30% PhDs)



**Spin-off** van **ULB**,  
Genoteerd op **Euronext**  
**Brussel & Parijs**



An aerial photograph of a vast agricultural landscape. The foreground and middle ground are filled with large, circular and irregularly shaped fields in various shades of green and brown, suggesting different crops or stages of cultivation. Two hot air balloons are visible in the sky: one is large and colorful with a geometric pattern, and the other is smaller and yellow. In the background, there are rolling hills and a body of water under a clear blue sky.

# RESHAPING THE ORTHOPAEDIC LANDSCAPE

CREËREN VAN INNOVATIEVE CELTHERAPIEËN  
VOOR ERNSTIGE BOTAANDOENINGEN

# HET SKELET



Verstoord in orthopedische  
aandoeningen en botziektes

# NADELEN VAN HUIDIGE ORTHOPEDISCHE BEHANDELINGEN



**Ingrijpende operaties**




**Relatief hoog aantal mislukte  
ingrepen en complicaties**





**Lange hospitalisatie  
en herstelperiode**

# UNIEKE TECHNOLOGIE VAN BOTVORMENDE CELLEN AFGELEID VAN STAMCELLEN UIT HET BEENMERG



# MET BELANGRIJKE VOORDELEN TEN OPZICHTE VAN BESTAANDE BEHANDELINGEN ...



**Actieve bot-  
vormende cellen**




**Minimaal invasief**




**Toepasbaar bij  
verschillende  
botaandoeningen**

... EN  
AANTOONBARE,  
STERKE  
BOTVORMENDE  
ACTIVITEIT  
IN PRE-KLINISCHE  
PROEVEN



# EEN GEVORDERDE KLINISCHE PIJPLIJN VOOR ORTHOPEDISCHE AANDOENINGEN MET HOGE MEDISCHE NODEN



# **FINALE FASE I/IIA STUDIERESULTATEN VOOR VERTRAAGD-HELENDE BREUKEN MET HET ALLOGEEN PRODUCT ALLOB**



# VERTRAAGD-HELENDE BREUKEN: EEN GROTE MARKT MET WEINIG THERAPEUTISCHE OPTIES...



> 700,000 gevallen vertraagd-helende breuken per jaar wereldwijd



Markt voor breukbehandeling groeit jaarlijks met 5+%



- “Wait & See” is de gangbare methode
- Zware belasting voor patient en omgeving

# SIGNIFICANTE RADIOLOGISCHE VERBETERING



Baseline




Toediening



Maand 6

**1,9X verbetering t.o.v. vooraf vastgelegde minimale verbetering**




**76% van de patiënten (16/21)**  
behalen de vereiste verbetering van 2 punten

Open-label Fase IIA studie met ALLOB voor vertraagd-helende breuken  
Finale resultaten na opvolging van 6 maanden (n=21)

TUS: Tomographic Union Score


# STERK HERSTEL IN KLINISCHE PARAMETERS

## Algemene gezondheidstoestand



\*\* p < 0,01 / \*\*\* p < 0,001

## Pijn aan breukzone



\* p < 0,05 / \*\*\* p < 0,001

### Veiligheid:


- ALLOB werd algemeen door alle patiënten goed verdragen

# OPTIMALISATIE VAN HET PRODUCTIEPROCES VAN HET ALLOGENE CELTHERAPIEPLATFORM VOOR EEN SUCCESVOLLE COMMERCIALISATIE



# DE KWALITEIT VAN DE PRODUCTIE IS CRUCIAAL VOOR HET SUCCES VAN OP DE MARKT BRENGEN VAN CELTHERAPIEPRODUCTEN

Wetenschappelijk  
concept



Klinische  
ontwikkeling



Goedgekeurde  
behandeling



## Sleutelfactoren voor een succesvol celtherapieproduct

- ✓ Consistentie
- ✓ Schaalbaarheid
- ✓ Rentabiliteit
- ✓ Efficiënte bevoorrading
- ✓ Gebruiksgemak



Optimalisatie  
productie-  
proces

# OPTIMALISATIE VAN ALLOB VOOR DE BEHANDELING VAN GROTE PATIËNTENPOPULATIES

Creëren van een celtherapieplatform op een commerciële schaal voor de behandeling van grote patiëntenpopulaties



**Verhoogde opbrengst  
(x 10.000)**



**Gecryopreserveerd  
eindproduct**



**Schaalvergroting &  
automatisering**



**Behandeling van grote  
patiëntenpopulaties**



**Consistente kwaliteit**



**Verlaging van kosten**

# OPTIMALISATIE VAN ALLOB VOOR DE BEHANDELING VAN GROTE PATIËNTENPOPULATIES

Creëren van een celtherapieplatform op een commerciële schaal voor de behandeling van grote patiëntenpopulaties



Verhoogde opbrengst  
(x 10.000)



Gecryopreserveerd  
eindproduct



Schaalvergroting &  
automatisering



Gestroomlijnde  
supply chain



Brede beschikbaarheid



“Kant en klaar” product

# TOEKOMSTIGE KLINISCHE ONTWIKKELING VAN ALLOB IN VERTRAAGD-HELENDE BREUKEN



- Door sterke tussentijdse resultaten in werkzaamheid werd de **patiëntenwerving** van de Fase IIA studie **voortijdig stopgezet** op aanbeveling van het veiligheidscontrole-comité (Data and Safety Monitoring Board - DSMB)
- De positieve eindresultaten bevestigen **ALLOB** verder als **sterk kandidaat-product**
- **Fase IIB studie** met **controle arm: voorbereiding** voor het indienen van het aanvraagdossier voor klinische studie (**CTA**) **gestart**

# Vragen?



# Contact

**Thomas LIENARD**

Chief Executive Officer

**Ching Man CHOI**

Manager Investor Relations

Telefoon: +32 (0) 71 12 10 00

Fax: +32 (0) 71 71 12 10 01

E-mail: [info@bonetherapeutics.com](mailto:info@bonetherapeutics.com)

Website: [www.bonetherapeutics.com](http://www.bonetherapeutics.com)



Wallonie

